Natural history and prognosis of untreated stage I epithelial ovarian carcinoma

被引:140
作者
Ahmed, FY [1 ]
Wiltshaw, E [1 ]
AHern, RP [1 ]
Nicol, B [1 ]
Shepherd, J [1 ]
Blake, P [1 ]
Fisher, C [1 ]
Gore, ME [1 ]
机构
[1] ROYAL MARSDEN HOSP,DEPT MED,GYNAECOL UNIT,LONDON SW3 6JJ,ENGLAND
关键词
D O I
10.1200/JCO.1996.14.11.2968
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The aim of this study was to investigate the independent significance of prognostic factors in stage I invasive epithelial ovarian cancer (EOC). Patients and Methods: Between 1980 and 1994, all patients with stage I EOC (borderline tumors excluded) following surgical resection were entered onto this study, No patient received adjuvant therapy and patients were monitored as follows: years 1 to 2-physical examination and serum CA125 every 3 months and computed tomographic (CT) scan every 6 months; years 3 to 5-physical examination and serum CA 125 every 6 months and CT scan yearly; years 5 to 10-annual physical examination and serum CA125, with CT scan if clinically indicated. Results: A total of 194 patients entered the study. The median patient age was 54 years (range, 15 to 83), and the median follow-up duration 54 months (range, 7 to 157). Five-year survival rates were as follows: stage IA, 93.7%; stage IB, 92%; and stage IC, 84%. Multivariate analysis using Cox's regression identified grade (P <.001), presence of ascites (P=.05), and surface tumor (P <.01) as independent poor prognostic factors, International Federation of Gynecology and Obstetrics (FIGO) substage did not appear to have independent prognostic significance, Intraoperative capsule rupture was not found to be prognostically significant, The impact of preoperative rupture remains unclear. Conclusion: This is on important series, as no patient received adjuvant therapy, and represents the natural history of surgically resected stage I EOC. (C) 1996 by American Society of Clinical Oncology.
引用
收藏
页码:2968 / 2975
页数:8
相关论文
共 24 条
[1]  
[Anonymous], 1979, HDB REP RES CANC TRE
[2]   PROGNOSTIC FACTORS AND ADJUVANT TREATMENT IN EARLY EPITHELIAL OVARIAN-CANCER [J].
BERTELSEN, K ;
HOLUND, B ;
ANDERSEN, JE ;
NIELSEN, K ;
STROYER, I ;
LADEHOFF, P .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1993, 3 (04) :211-218
[3]   Adjuvant treatment for early epithelial ovarian cancer: Results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (P-32) [J].
Bolis, G ;
Colombo, N ;
Pecorelli, S ;
Torri, V ;
Marsoni, S ;
Bonazzi, C ;
Chiari, S ;
Favalli, G ;
Mangili, C ;
Presti, M ;
Zanaboni, F ;
Mangioni, C .
ANNALS OF ONCOLOGY, 1995, 6 (09) :887-893
[4]  
*CANC RES CAMP, 1994, FACTSH 1 3 INC UK
[5]  
DEMBO AJ, 1990, OBSTET GYNECOL, V75, P263
[6]   PELVIC AND PARA-AORTIC LYMPHADENECTOMY IN CANCER OF THE OVARY [J].
DIRE, F ;
FONTANELLI, R ;
RASPAGLIESI, F ;
DIRE, E .
BAILLIERES CLINICAL OBSTETRICS AND GYNAECOLOGY, 1989, 3 (01) :131-142
[7]  
EINHORN N, 1985, CANCER, V55, P2019, DOI 10.1002/1097-0142(19850501)55:9<2019::AID-CNCR2820550932>3.0.CO
[8]  
2-2
[9]   IS STAGE-I EPITHELIAL OVARIAN-CANCER OVERTREATED BOTH SURGICALLY AND SYSTEMICALLY - RESULTS OF A 5-YEAR CANCER REGISTRY REVIEW [J].
FINN, CB ;
LUESLEY, DM ;
BUXTON, EJ ;
BLACKLEDGE, GR ;
KELLY, K ;
DUNN, JA ;
WILSON, S .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1992, 99 (01) :54-58
[10]  
*GROPP INT COOP ON, 1987, LANCET, V2, P353